Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apramycin - Juvabis Therapeutics

Drug Profile

Apramycin - Juvabis Therapeutics

Latest Information Update: 11 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aventis
  • Developer Aventis; Juvabis Therapeutics
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections
  • No development reported Cancer

Most Recent Events

  • 26 Sep 2019 Juvabis Therapeutics plans a phase I trial for Apramycin in healthy volunteers in Germany (IV, Infusion) (NCT04105205)
  • 25 Sep 2019 Phase-I clinical trials in Gram-negative infections (In volunteers) in Germany (IV, Infusion) (NCT04105205)
  • 04 May 2018 Antimicrobial data from preclinical studies in Gram negative infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top